Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US40131M1099
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG006D97VY9
GH
Guardant Health Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Diagnostics & Research · THEMEFOLIO: $HLTH
NAME
Guardant Health Inc
ISIN
US40131M1099
TICKER
GH
MIC
XNAS
REUTERS
GH.OQ
BLOOMBERG
GH US
Mo., 29.12.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Guardant Health’s management is scheduled to present and participate in a Q&A session on Monday, January 12, at 3:45 p.m. Pacific Time / 6:45 p....
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 11.12.2025       Guardant Health
US40131M1099

Guardant Health (Nasdaq: GH), a leading precision oncology company, and Trial Library, an AI technology company enabling oncology clinical trials as a care option, today announced a strategic collaboration to increase access to cancer clinical trials in the United States. The collaboration combines Guardant Health’s suite of cutting-edge precisio...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 09.12.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guar...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Fr., 05.12.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025. Oral presentations will highlight...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 12.11.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the public launch of the Single Namespace Working Group (SNS), a 34-member, cross-industry consortium which has drafted the first open standard for exabyte-scale data interoperability. Managing exabyte-scale data across different storage providers is often di...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 10.11.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its Guardant Reveal® blood test to include late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal tracks more than 20,000 epigenomic (methylation) signals to measure changes in circulating tumor DNA (ctDNA) lev...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Fr., 07.11.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UK Fireside chat on Wednesday, November 19 at 9:30 a.m. Greenwich Mean Time Piper Sandler 37th Annual Healthcare Conference in New...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Fr., 07.11.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 21, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 184,961 shares of its common stock to 272 new non-executive employees and one non-qualified stock optio...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating that its Guardant Reveal® blood test helps clinicians to assess the effectiveness of chemotherapy in patients with advanced solid tumors months earlier than conventional methods. This is the first robust clinical validation study of pan...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 05.11.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in screening for colorectal cancer (CRC). Shield is the first and only blood test to receive FDA app...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 05.11.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million aggregate principal amount of 0% convertible senior notes due 2033 (the “notes”) in a private offering (the “convertible notes offering”) to persons reasonably believed to be qualified...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 05.11.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 3,333,333 shares of Guardant Health’s common stock at a public offering price of $90.00 per share (the “common stock offering”). The size of the common stock offering was increased...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the commencement of an underwritten public offering of $250.0 million of shares of Guardant Health’s common stock (the “common stock offering”). Guardant Health also intends to grant the underwriters a 30-day option to purchase up to an ad...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $300.0 million aggregate principal amount of convertible senior notes due 2033 (the “notes”) in a private offering (the “convertible notes offering”) to persons reasonably believed to be qualified institutional buyer...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 29.10.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights For the three-month period ended September 30, 2025, as compared to the same period of 2024: Reported total revenue of $265.2 million, an increase of 39%...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 27.10.2025       Guardant Health
US40131M1099

Guardant Health (Nasdaq: GH), a leading precision oncology company, and Zephyr AI, a leader in precision medicine harnessing artificial intelligence to accelerate drug development, today announced a strategic partnership to deliver novel, scalable, and actionable insights that support biopharmaceutical innovation. This collaboration will combine u...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
So., 26.10.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona taking place Frida...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 15.10.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that new data from across its oncology portfolio will be presented in 15 accepted abstracts at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. These presentations span the cancer care treatment co...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 09.10.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the we...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 15.09.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans’ health car...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 11.09.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has reached a strategic agreement with LabFlorida/SunDx Labs to provide residents of senior living communities access to Guardant Shield™, the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for colore...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 08.09.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic partnership with PathGroup, one of the nation’s leading partners to physicians, hospitals, and healthcare networks nationwide, to significantly expand the reach of Guardant’s FDA-approved Shield™ blood test. The partnership will bring Shield to mo...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 04.09.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a positive clinical readout update assessing the performance of the latest colorectal cancer (CRC) screening algorithm (V2) for its Shield™ blood test. The study met all primary endpoints and the sensitivity of this new screening algorithm for detecting CRC w...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 28.08.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be hosting an Investor Day on September 24, 2025, in New York City, NY starting at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. The event will feature presentations by several members of the company's leadership team. Interested parties...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 26.08.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Guardant Health’s management is scheduled to participate in a fireside chat on Monday, September 8th at 4:05 p.m. ET. Interested parties ma...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Fr., 15.08.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 22, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 239,565 shares of its common stock to 189 new non-executive employees and two non-qualified stock option a...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 31.07.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Guardant Health’s management is scheduled to participate in a fireside chat on Wednesday, August 13th at 9:30 a.m. ET. Interested parties may access...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 30.07.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights For the three-month period ended June 30, 2025, as compared to the same period of 2024: Reported total revenue of $232.1 million, an increase of 31%, driven...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 30.07.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and health advocate James Van Der Beek to increase awareness about colorectal cancer (CRC) screening and the Shield™ blood test. Approved by the U.S. Food and Drug Administration (FDA) last year, Shield offers a convenient and more...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 29.07.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the first clinical readout from their collaboration in the RADIOHEAD study with the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world. The data, published today in Cancer Re...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 15.07.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 14.07.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webc...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 10.06.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world’s most urgent challenges. Shield is...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 09.06.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company’s minimal residual disease (MRD) blood test, in predicting recurrence in...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 03.06.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 02.06.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the National Comprehensive Cancer Network (NCCN) has included the Shield blood test in its updated colorectal cancer (CRC) screening guidelines. The Shield test detects CRC signals in the bloodstream from DNA that is shed by tumors, called circulating tu...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 02.06.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the results of the Phase III SERENA-6 trial - sponsored by AstraZeneca - demonstrate the clinical value of the Guardant360® CDx test in a circulating tumor DNA-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of radiologi...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Sa., 31.05.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and its research collaborators today presented results of the largest study to date evaluating circulating tumor DNA (ctDNA) in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal™ test to stratify the risk of disease recurrence and overall s...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 27.05.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the Guardant 360® Liquid test that greatly expand its biomarker identification and cancer subtyping capabilities to help oncologists identify optimal treatment plans. The expanded applications are enabled through the multiomic profiling...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 22.05.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from more than 19 studies, including a landmark plenary session on the Phase 3 SERENA-6 trial, demonstrating the critical role of Guardant liquid biopsy tests in cancer screening, therapy selection...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 21.05.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company’s portfolio of tumor molecular profiling tests. This new set of tests will help oncologists identify tumor subtypes and match cancer patients to the most effective targeted ther...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 20.05.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Guardant Hereditary Cancer test, a germline test that identifies genetic variants associated with cancer risk to help cancer care teams provide optimal patient care. Germline genetic testing is recommended by medical practice guidelines for...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 08.05.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BofA Securities 2025 Healthcare Conference in Las Vegas, NV Fireside chat on Wednesday, May 14th at 3:40 p.m. Pacific Time Jefferies Global Healthcare Conference in New York, NY Fir...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 08.05.2025       Guardant Health
US40131M1099

Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company. The list recognizes and honors the top 100 most influential people in global health this year. “The inclusion on TIME100 Health’s list is more than a personal honor,” said AmirAli...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 157,466 shares of its common stock to 139 new non-executive employees and two non-qualified stock option...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 30.04.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 29.04.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its methylation-based Shield™ multi-cancer detection (MCD) test demonstrated high specificity and clinically meaningful sensitivity across ten tumor types,* while also providing information to guide clinical diagnostic evaluatio...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 28.04.2025       Guardant Health
US40131M1099

Throughout release, "exome-wide" should read as "genome-wide". The updated release reads: GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 28.04.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Guardant360® Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis—including DNA, RNA, AI-powered PD-L1 and exome-wide methylation data—to provide researchers and cancer care teams with a...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 24.04.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE: PFE), to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity™ smart liquid biopsy platform. Under the multi-year collaboration agreement, Guardant and Pfi...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink